Theresa Heggie

Theresa Marie Heggie currently works at BioCryst Pharmaceuticals, Inc., as Independent Director from 2018, Alnylam Germany GmbH, as Co-Managing Director, Alnylam UK Ltd., as Director from 2017, and ProQR Therapeutics NV, as Member-Supervisory Board from 2023.
Ms. Heggie also formerly worked at Shire Orphan Therapies GmbH, as Chief Executive Officer from 2008 to 2009, Spur Therapeutics Ltd., as Chief Executive Officer, Freeline Therapeutics Holdings Ltd., as Chief Executive Officer & Director, Swedish Orphan Biovitrum AB, as Independent Non-Executive Director from 2016 to 2017, Baxter International, Inc., as Vice President-Global Marketing, Janssen Pharmaceuticals, Inc., as Principal, Shire Plc, as Senior Vice President-Global Commercial Operations from 2005 to 2008, The British United Provident Association Ltd., as Chief Marketing & Strategy Officer from 2013 to 2016, Alnylam Pharmaceuticals, Inc., as Senior Vice President, Head-EMEA & Canada Region from 2017 to 2020, Shire Human Genetic Therapies, Inc., as Senior Vice President-Global Commercial Operations from 2010 to 2013, Ohmeda Pharmaceuticals, as Principal, and ProQR Therapeutics NV, as Chief Commercial Officer from 2021 to 2022.
Ms. Heggie received her undergraduate degree from Cornell University.